Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of 0.00% and -24.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named a GenomeWeb 2026 Best Places to Work honoree, marking its second consecutive year in the annual program recognizing top workplaces across the life sciences research, diagnostics and precision medicine sectors.
Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.
Detailed price information for Lucid Diagnostics Inc (LUCD-Q) from The Globe and Mail including charting and trades.
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced advances in multiple payment, billing, and coding pathways for its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device, following three public meetings held last week.
This is the newest page. Registered accounts read further back.